Lung Cancer Management最新文献

{"title":"Bilateral synchronous multiple lung cancer: an emerging problem","authors":"Huajian Liu, Liam Polley","doi":"10.2217/lmt-2023-0008","DOIUrl":"https://doi.org/10.2217/lmt-2023-0008","url":null,"abstract":"Aim: Multiple primary lung cancers are becoming increasingly recognised and pose diagnostic and staging uncertainties with challenging management options and prognostication. Case report: We describe a case of synchronous multiple primary lung cancer occurring bilaterally, and the steps in reaching the diagnosis, initial surgical management, the intensive follow-up this underwent, and how its subsequent recurrence led to treatment with radiation therapy in light of the patient's declining fitness. Discussion: This case highlighted that cytological recurrence could occur prior to radiological recurrence, especially for endobronchial tumors, and intensive follow-up both radiologically and endoscopically with multidisciplinary input is crucial in the management of these challenging cases where evidence-based guidelines are limited.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"120 11","pages":""},"PeriodicalIF":2.8,"publicationDate":"2023-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138959664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A retrospective study of ensartinib-treated <i>ALK</i>-positive locally advanced or metastatic NSCLC patients in China","authors":"Xiaobin Yuan, Yang Wang, Min Yang, Pengxiang Wu, Hui Chen, Yu Yun, Zhilin Shen, Dong Ji, Yongbin Ma, Lieming Ding","doi":"10.2217/lmt-2023-0005","DOIUrl":"https://doi.org/10.2217/lmt-2023-0005","url":null,"abstract":"Aim: This retrospective study aimed to assess the efficacy and safety of ensartinib in Chinese patients with ALK-positive advanced NSCLC in real-world clinical practice. Methods: Clinical data from ALK-positive NSCLC patients treated with ensartinib in China were collected and analyzed. Efficacy end points included objective response rate and progression-free survival. Safety profiles were also evaluated. Results: A total of 682 patients were included in this study. The study demonstrated promising efficacy with an objective response rate of 54.0%, and the median progression-free survival was not estimable. Ensartinib exhibited a manageable safety profile with treatment-related adverse events (TRAEs) consistent with prior clinical trials. The most common TRAE was rash (21.1%) and no TRAE led to death. Conclusion: Ensartinib is active and well tolerated for ALK-positive NSCLC patients in real-world clinical settings.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"232 3","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135476086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival and quality-of-life outcomes in early-stage NSCLC patients: a literature review of real-world evidence.","authors":"Nick Jovanoski,&nbsp;Kathleen Bowes,&nbsp;Audrey Brown,&nbsp;Rossella Belleli,&nbsp;Danilo Di Maio,&nbsp;Shkun Chadda,&nbsp;Seye Abogunrin","doi":"10.2217/lmt-2023-0003","DOIUrl":"https://doi.org/10.2217/lmt-2023-0003","url":null,"abstract":"<p><strong>Aim: </strong>Assess the long-term survival and quality-of-life outcomes in early-stage NSCLC (eNSCLC) patients.</p><p><strong>Methods: </strong>Review of long-term survival and quality-of-life after curative treatment in eNSCLC patients in observational studies.</p><p><strong>Results: </strong>Disease-free proportion decreased in stage III vs stage I patients. Recurrence-free proportion decreased with age and disease stage. Advanced stage and vascular invasion increased risk of late recurrence. Conditional 5-year relative survival rates did not exceed 87%, indicating higher mortality in eNSCLC survivors. Lower conditional survival rates and relative survival rates were associated with older age and advanced disease. Survivors of eNSCLC had poorer physical quality-of-life.</p><p><strong>Conclusion: </strong>Despite curative-intent therapy, survivors of eNSCLC still face significant risks of recurrence, excess mortality, and diminished quality-of-life.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"12 3","pages":"LMT60"},"PeriodicalIF":2.8,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/19/bb/lmt-12-60.PMC10485735.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10223049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alectinib for treating patients with metastatic <i>ALK</i>-positive NSCLC: systematic review and network metanalysis.","authors":"Daniel Samacá-Samacá,&nbsp;Laura Prieto-Pinto,&nbsp;Andrés Yepes Peréz,&nbsp;Carolina Valderrama,&nbsp;Fabián Hernández","doi":"10.2217/lmt-2022-0018","DOIUrl":"https://doi.org/10.2217/lmt-2022-0018","url":null,"abstract":"<p><strong>Aim: </strong>To compare the efficacy and safety of alectinib with other ALK inhibitors in treating patients with metastatic or locally advanced <i>ALK</i>-positive NSCLC.</p><p><strong>Methods: </strong>A systematic literature review was conducted up to November 2021. Network meta-analyses were performed using the frequentist method (random effects). GRADE evidence profile was conducted.</p><p><strong>Results: </strong>13 RCTs were selected. For overall survival, alectinib was found to reduce the risk of death compared with crizotinib. In progression-free survival, alectinib reduced the risk of death or progression compared with crizotinib and ceritinib. Subgroup analysis by brain metastasis at baseline showed the superiority of alectinib over crizotinib and a similar effect compared with second-and third-generation inhibitors. Alectinib showed a good safety profile compared with the other ALK inhibitors.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"12 2","pages":"LMT59"},"PeriodicalIF":2.8,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/04/ba/lmt-12-59.PMC10242442.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9955054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world outcomes and toxicity of adjuvant chemotherapy in NSCLC: a single-center experience.","authors":"Christopher Cronin,&nbsp;Shahid Iqbal,&nbsp;Abdul R Farooq,&nbsp;Pauline O'Dea,&nbsp;Louise Burke,&nbsp;Seamus O'Reilly,&nbsp;Deirdre O'Mahony,&nbsp;Derek G Power,&nbsp;Richard M Bambury,&nbsp;Dearbhaile C Collins","doi":"10.2217/lmt-2022-0014","DOIUrl":"https://doi.org/10.2217/lmt-2022-0014","url":null,"abstract":"<p><strong>Aim: </strong>Adjuvant chemotherapy in NSCLC is associated with modest benefits and significant toxicity. We sought to evaluate the toxicity of adjuvant chemotherapy and disease-specific outcomes in a real-world population.</p><p><strong>Methods: </strong>We performed a retrospective analysis of patients undergoing adjuvant chemotherapy for NSCLC in an Irish center over a 7-year period. We described treatment-associated toxicity, recurrence-free survival and overall survival.</p><p><strong>Results: </strong>62 patients underwent adjuvant chemotherapy. Treatment-associated hospitalisation occurred in 29% of patients. Relapse was recorded in 56% of patients and median recurrence-free survival was 27 months.</p><p><strong>Conclusion: </strong>High rates of disease recurrence and treatment-associated morbidity were observed in patients receiving adjuvant chemotherapy for NSCLC. Novel therapeutic strategies are required to improve outcomes in this population.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"12 1","pages":"LMT58"},"PeriodicalIF":2.8,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/92/4b/lmt-12-58.PMC10241113.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9591368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implementing physician education to increase lung cancer screening uptake.","authors":"Coral Olazagasti,&nbsp;Nagashree Seetharamu,&nbsp;Nina Kohn,&nbsp;David Steiger","doi":"10.2217/lmt-2022-0008","DOIUrl":"https://doi.org/10.2217/lmt-2022-0008","url":null,"abstract":"<p><strong>Aim: </strong>Lung cancer (LC) is the leading cause of cancer-related deaths worldwide. The US Preventive Services Task Force and National Comprehensive Cancer Network recommend annual low-dose computed tomography (LDCT) for eligible adults. We conducted a study to assess physician LDCT referral patterns.</p><p><strong>Methods: </strong>The study was divided into a pre-, intervention, and post-intervention periods. The intervention was a LC screening educational series. We evaluated rates of LDCT screening referrals during pre- and post-intervention periods.</p><p><strong>Results: </strong>In the pre-intervention period, 75 patients fulfilled US Preventive Services Task Force and/or National Comprehensive Cancer Network criteria and 27% underwent LDCT. In the post-intervention period, 135 patients fulfilled either screening criteria of whom 61.5% underwent LDCT.</p><p><strong>Conclusion: </strong>In our study, educational lectures improved compliance significantly and should be used as tool for primary care providers to effectively increase LDCT screening referrals.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"11 2","pages":"LMT55"},"PeriodicalIF":2.8,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7e/9c/lmt-11-55.PMC10135441.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9392586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proportion of biopsy specimens containing a tumor when compared to all biopsy specimens by transbronchial biopsy.","authors":"Shinnosuke Takemoto,&nbsp;Mutsumi Ozasa,&nbsp;Remi Mizuta,&nbsp;Ryuta Tagawa,&nbsp;Sawana Ono,&nbsp;Noritaka Honda,&nbsp;Takayuki Suyama,&nbsp;Yasuhiro Umeyama,&nbsp;Yosuke Dotsu,&nbsp;Hiroshi Gyotoku,&nbsp;Hiroyuki Yamaguchi,&nbsp;Kazuko Yamamoto,&nbsp;Noriho Sakamoto,&nbsp;Yasushi Obase,&nbsp;Minoru Fukuda,&nbsp;Hiroshi Mukae","doi":"10.2217/lmt-2022-0001","DOIUrl":"https://doi.org/10.2217/lmt-2022-0001","url":null,"abstract":"<p><strong>Background: </strong>The lung cancer biopsy specimens obtained by endobronchial ultrasound-guide sheath (EBUS-GS) trans lung biopsy occasionally do not contain cancer cells. It is a problem that there is a possibility that they may not contain cancer cells.</p><p><strong>Aim of the study: </strong>To investigate the proportion of biopsy specimens containing cancer cells in total biopsy specimens.</p><p><strong>Materials & methods: </strong>Patients with lung cancer diagnosed by EBUS-GS were selected. The primary end point was the proportion of specimens containing tumors in the total specimens obtained by EBUS-GS.</p><p><strong>Results: </strong>Twenty-six patients were investigated. The percentage of specimens containing cancer cells in the total specimens was 79.0%.</p><p><strong>Conclusion: </strong>The proportion of biopsy specimens containing cancer cell to all biopsy specimens by EBUS-GS was high, but not 100%.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"11 4","pages":"LMT57"},"PeriodicalIF":2.8,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/29/50/lmt-11-57.PMC10241111.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9591410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment considerations for patients with advanced squamous cell carcinoma of the lung: a plain language summary.","authors":"Edgardo S Santos,&nbsp;Estelamari Rodriguez","doi":"10.2217/lmt-2022-0017","DOIUrl":"https://doi.org/10.2217/lmt-2022-0017","url":null,"abstract":"<p><strong>What is this article about?: </strong>This plain language summary reports the key points of a recent review article that discussed current treatment options for a type of cancer called squamous cell carcinoma (SCC) of the lung.</p><p><strong>What is scc of the lung?: </strong>SCC of the lung is a type of non-small-cell lung cancer (NSCLC for short) that is usually linked with smoking. It can be difficult to treat because it is often diagnosed after it has spread to other parts of the body.</p><p><strong>What first-line treatment options are available for people with scc of the lung?: </strong>Most patients receive a combination of chemotherapy and immunotherapy as their first-line treatment (the first treatment they receive after their diagnosis). Immunotherapy drugs have improved how long people with SCC of the lung can live for. However, for most patients, they eventually stop working. At this point, other second-line treatments are considered, meaning treatments patients receive after their first-line treatment is stopped due to side effects or because it no longer works.</p><p><strong>What second-line treatment options are available to people with scc of the lung?: </strong>Immunotherapy drugs were originally developed as second-line options after chemotherapy. However, immunotherapy drugs are now used with chemotherapies as first-line treatments. This has left a gap for second-line treatment options. There are some drugs available for second-line treatment, such as afatinib, which comes as a tablet, and docetaxel with or without ramucirumab, which is given as an infusion. Other potential treatments are being developed.</p><p><strong>What emerging treatment options are being developed?: </strong>Some early clinical trials of potential treatments have shown promise, but more results are needed. Research into the genetic mutations linked with the development of SCC of the lung is also ongoing. It is hoped that this will help identify patients who might benefit from specific treatments.</p><p><strong>Who should read this article?: </strong>People with SCC of the lung and their caregivers, patient advocates, and healthcare professionals, including those who are helping people learn about scientific discoveries and potential new therapeutic strategies.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"11 3","pages":"LMT56"},"PeriodicalIF":2.8,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cf/84/lmt-11-56.PMC10241114.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9589951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genomic epidemiology reveals the impact of national and international restrictions measures on the SARS-CoV-2 epidemic in Brazil.","authors":"Marta Giovanetti, Svetoslav Nanev Slavov, Vagner Fonseca, Eduan Wilkinson, Houriiyah Tegally, José Salvatore Leister Patané, Vincent Louis Viala, James Emmanuel San, Evandra Strazza Rodrigues, Elaine Vieira Santos, Flavia Aburjaile, Joilson Xavier, Hegger Fritsch, Talita Emile Ribeiro Adelino, Felicidade Pereira, Arabela Leal, Felipe Campos de Melo Iani, Glauco de Carvalho Pereira, Cynthia Vazquez, Gladys Mercedes Estigarribia Sanabria, Elaine Cristina de Oliveira, Luiz Demarchi, Julio Croda, Rafael Dos Santos Bezerra, Loyze Paola Oliveira de Lima, Antonio Jorge Martins, Claudia Renata Dos Santos Barros, Elaine Cristina Marqueze, Jardelina de Souza Todao Bernardino, Debora Botequio Moretti, Ricardo Augusto Brassaloti, Raquel de Lello Rocha Campos Cassano, Pilar Drummond Sampaio Corrêa Mariani, João Paulo Kitajima, Bibiana Santos, Rodrigo Proto-Siqueira, Vlademir Vicente Cantarelli, Stephane Tosta, Vanessa Brandão Nardy, Luciana Reboredo de Oliveira da Silva, Marcela Kelly Astete Gómez, Jaqueline Gomes Lima, Adriana Aparecida Ribeiro, Natália Rocha Guimarães, Luiz Takao Watanabe, Luana Barbosa Da Silva, Raquel da Silva Ferreira, Mara Patricia F da Penha, María José Ortega, Andrea Gómez de la Fuente, Shirley Villalba, Juan Torales, María Liz Gamarra, Carolina Aquino, Gloria Patricia Martínez Figueredo, Wellington Santos Fava, Ana Rita C Motta-Castro, James Venturini, Sandra Maria do Vale Leone de Oliveira, Crhistinne Cavalheiro Maymone Gonçalves, Maria do Carmo Debur Rossa, Guilherme Nardi Becker, Mayra Marinho Presibella, Nelson Quallio Marques, Irina Nastassja Riediger, Sonia Raboni, Gabriela Mattoso Coelho, Allan Henrique Depieri Cataneo, Camila Zanluca, Claudia N Duarte Dos Santos, Patricia Akemi Assato, Felipe Allan da Silva da Costa, Mirele Daiana Poleti, Jessika Cristina Chagas Lesbon, Elisangela Chicaroni Mattos, Cecilia Artico Banho, Lívia Sacchetto, Marília Mazzi Moraes, Rejane Maria Tommasini Grotto, Jayme A Souza-Neto, Maurício Lacerda Nogueira, Heidge Fukumasu, Luiz Lehmann Coutinho, Rodrigo Tocantins Calado, Raul Machado Neto, Ana Maria Bispo de Filippis, Rivaldo Venancio da Cunha, Carla Freitas, Cassio Roberto Leonel Peterka, Cássia de Fátima Rangel Fernandes, Wildo Navegantes de Araújo, Rodrigo Fabiano do Carmo Said, Maria Almiron, Carlos Frederico Campelo de Albuquerque E Melo, José Lourenço, Tulio de Oliveira, Edward C Holmes, Ricardo Haddad, Sandra Coccuzzo Sampaio, Maria Carolina Elias, Simone Kashima, Luiz Carlos Junior de Alcantara, Dimas Tadeu Covas","doi":"10.1101/2021.10.07.21264644","DOIUrl":"10.1101/2021.10.07.21264644","url":null,"abstract":"<p><p>Brazil has experienced some of the highest numbers of COVID-19 cases and deaths globally and from May 2021 made Latin America a pandemic epicenter. Although SARS-CoV-2 established sustained transmission in Brazil early in the pandemic, important gaps remain in our understanding of virus transmission dynamics at the national scale. Here, we describe the genomic epidemiology of SARS-CoV-2 using near-full genomes sampled from 27 Brazilian states and a bordering country - Paraguay. We show that the early stage of the pandemic in Brazil was characterised by the co-circulation of multiple viral lineages, linked to multiple importations predominantly from Europe, and subsequently characterized by large local transmission clusters. As the epidemic progressed under an absence of effective restriction measures, there was a local emergence and onward international spread of Variants of Concern (VOC) and Variants Under Monitoring (VUM), including Gamma (P.1) and Zeta (P.2). In addition, we provide a preliminary genomic overview of the epidemic in Paraguay, showing evidence of importation from Brazil. These data reinforce the usefulness and need for the implementation of widespread genomic surveillance in South America as a toolkit for pandemic monitoring that provides a means to follow the real-time spread of emerging SARS-CoV-2 variants with possible implications for public health and immunization strategies.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978948/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90208758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exceptional response to afatinib in a patient with persistent G719A EGFR-mutant NSCLC","authors":"A. Kulkarni, N. Fujioka, Lucia Reinhardt, Manish R. Patel, R. Kratzke","doi":"10.2217/lmt-2021-0001","DOIUrl":"https://doi.org/10.2217/lmt-2021-0001","url":null,"abstract":"We present a patient with metastatic NSCLC harboring a compound EGFR mutation with co-occurring G719A and T790M mutation. T790M mutation was treatment emergent mutation when patient was on early generation tyrosine kinase inhibitors. Initial Guardant 360 showed that G719A was the dominant clone. Following, osimertinib, the patient had only a radiographic disease stabilization and then developed both clinical and radiographic progression. On progression, T790M was undetectable but G719A continued to be the dominant clone. Subsequent administration of afatinib led to a clinical and radiological response. To our knowledge, this is the first case report describing co-occurrence of EGFR G719A and T790M mutations and the clonal evolution during treatment with anti-EGFR therapies.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42910291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}